Exercise Ventilatory Inefficiency in Post-COVID-19 Syndrome: Insights from a Prospective Evaluation

Álvaro Aparisi, Cristina Ybarra-Falcón, Mario García-Gómez, Javier Tobar, Carolina Iglesias-Echeverría, Sofía Jaurnieto-Largo, Raquel Ladrón, Aitor Uribarri, Pablo Catalá, Williams Hinojosa, Marta Marcos-Mangas, Laura Fernández-Prieto, Rosa Sedano-Gutiérrez, Iván Cusacovich, David Andaluz-Ojeda, Blanca de Vega-Sánchez, Amada Recio-Platero, Esther Sanz-Patiño, Dolores Calvo, Carlos Baladrón, Manuel Carrasco-Moraleja, Carlos Disdier-Vicente, Ignacio J. Amat-Santos, and J. Alberto San Román

Abstract: Introduction: Coronavirus disease 2019 (COVID-19) is a systemic disease characterized by a disproportionate inflammatory response in the acute phase. This study sought to identify clinical sequelae and their potential mechanism. Methods: We conducted a prospective single-center study (NCT04689490) of previously hospitalized COVID-19 patients with and without dyspnea during mid-term follow-up. An outpatient group was also evaluated. They underwent serial testing with a cardiopulmonary exercise test (CPET), transthoracic echocardiogram, pulmonary lung test, six-minute walking test, serum biomarker analysis, and quality of life questionnaires. Results: Patients with dyspnea (n = 41, 58.6%), compared with asymptomatic patients (n = 29, 41.4%), had a higher proportion of females (73.2 vs. 51.7%; p = 0.065) with comparable age and prevalence of cardiovascular risk factors. There were no significant differences in the transthoracic echocardiogram and pulmonary function test. Patients who complained of persistent dyspnea had a significant decline in predicted peak VO2 consumption (77.8 (64–92.5) vs. 99 (88–105); p < 0.00; p < 0.001), total distance in the six-minute walking test (535 (467–600) vs. 611 (550–650) meters; p = 0.001), and quality of life (KCCQ-23 60.1 ± 18.6 vs. 82.8 ± 11.3; p < 0.001). Additionally, abnormalities in CPET were suggestive of an impaired ventilatory efficiency (VE/VC slope 32.1–37.4 vs. 29.4 (26.9–31.4); p = 0.022) and high PETCO2 (34.5 (32–39) vs. 38 (36–40); p = 0.025). Interpretation: In this study, >50% of COVID-19 survivors present a symptomatic functional impairment irrespective of age or prior hospitalization. Our findings suggest a potential ventilation/perfusion mismatch or hyperventilation syndrome.
Keywords: post-COVID-19 syndrome; cardiopulmonary exercise testing; six-minute walking test; pulmonary function test; dyspnea; ventilatory inefficiency

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly virulent novel coronavirus and the cause of coronavirus disease 2019 (COVID-19). It triggers a strong immune response that becomes dysregulated and leads to systemic organ damage [1]. The estimated COVID-19 global mortality is 2.6% [2].

Most of the current knowledge of the disease has been directed toward the acute phase. Early reports during follow-up studies have reported that fatigue and dyspnea might affect up to 40% of COVID-19 survivors [3,4]. Furthermore, previous studies after hospital discharge have demonstrated abnormal pulmonary function tests in the early convalescent phase among COVID-19 survivors [5–7], with similar findings described after a three-month follow-up [8]. This fact suggests that there might be a great number of SARS-CoV-2 survivors presenting residual disabilities as has been demonstrated for alternative highly virulent coronaviruses [9,10].

To address this gap, the present study sought to explore the mid-term clinical course of COVID-19 survivors. We therefore described any clinical sequelae, persistent inflammatory parameters, pulmonary function, myocardial performance, and quality of life (QoL) with special emphasis on exercise capacity.

2. Materials and Methods

2.1. Study Design and Patient Selection

We conducted a single-center prospective study (NCT04689490) of patients with prior hospitalization because of COVID-19 who were admitted between March 2020 and April 2020. All eligible patients underwent a pre-specified follow-up 3 months after discharge with subsequent visits. A group of consecutive patients diagnosed with SARS-CoV-2 infection in the last fortnight of the study period who did not require hospital admission was also selected. Exclusion criteria were age < 18 years old, pregnancy, terminally ill patients, active SARS-CoV-2 infection, inability to exercise, and previous known severe cardiopulmonary disease.

All patients underwent a clinical assessment for symptom burden, evaluation of quality of life (QoL) with the Kansas City Cardiomyopathy Questionnaire (KCCQ) [11], venous blood sampling, resting echocardiography, six-minute walking test (6-MWT), tests of lung function (spirometry and diffusing capacity of the lungs for carbon monoxide), and treadmill cardiopulmonary exercise testing (CPET). All patients yielded a negative result in the reverse transcription polymerase chain reaction for SARS-CoV-2 48 h before the test of lung function and the CPET.

Patients were classified as post-discharge or ambulatory cohorts and subsequently as with or without dyspnea and compared. Patients were included in the dyspnea group if they reported New York Heart Association (NYHA) functional class ≥ II at the time of consultation.

The institutional local ethics committee approved the study protocol (CASVE PI-20-1894), and all patients provided written informed consent before inclusion. The work was carried out by following the guidelines of the Declaration of Helsinki of the World Medical Association.

2.2. Outcome Measure

The primary endpoint was self-reported functional capacity (reported as the NYHA) at 3 months after overcoming COVID-19, predicted peak oxygen consumption (V\text{O}_2) according to CPET, and predicted carbon monoxide diffusion capacity (DL\text{CO}). Secondary
endpoints included differences between (1) KCCQ score, (2) O2 pulse, (3) 6-MWT distance, (4) FEV1/FVC, (5) left ventricular ejection fraction (LVEF), and (6) inflammatory markers.

2.3. Clinical Laboratory Tests

We carried out all tests at a certified clinical laboratory (ISO 9001:2015). Ferritin and serum high-sensitivity C-reactive protein (hs-CRP) were measured by particle enhanced immunoturbidimetric and colorimetric assay, respectively (e501 Module Analyser®, Roche Diagnostics, Basel, Switzerland). Interleukin-6 (IL-6) was tested on IMMULITE® 2000 immunoassay system (IMMULITE® 2000 IL-6, Siemens Healthcare Diagnostic, Marburg, Germany). Quantification of biomarkers, such as the N-terminal prohormone of brain natriuretic peptide (NT-ProBNP) and the high-sensitivity T troponin (hs TnT) in plasma, were measured by electrochemiluminescence immunoassay with the analyzer Cobas® 6000 c 601 (Roche Diagnostics, Basel, Switzerland). D-dimer was obtained by a turbidimetric test with the ACL Top 500® hemostasis testing system (Werfen Company, Cuenca, Spain).

2.4. Resting Transthoracic Echocardiography

All patients underwent resting transthoracic echocardiography. All images were recorded in each of the standard projections in accordance with the recommendations of the American and European Societies of Echocardiography [12]. Images were analyzed offline using EchoPAC software (version 202) by two independent observers that determined valvular disease, myocardial deformation/strain (reported as global longitudinal strain), and diastolic function as well as right and left systolic ventricular function.

2.5. Pulmonary Function Test

Assessed pulmonary function tests were spirometry, lung volumes, and quantification of diffusion capacity for carbon monoxide (MasterScreen-Body/Diffusion; Sentry Suit v. 3.10) according to the recommendations of the European Respiratory Society [13,14]. At least three acceptable measurements were obtained. Recorded predicted parameters were forced expiratory volume in the 1st second (FEV1%), forced vital capacity (FVC%), FEV1/FVC ratio, residual volume (RV%), total lung capacity (TLC%), and diffusion capacity (DLCO% and KCO%).

2.6. Six-Minute Walking Test and Cardiopulmonary Exercise Test

The 6-MWT was performed according to standard methods [15]. In addition to the total distance and self-perceived exertion, pulse oxygen saturation and heart rate were recorded before and every minute until the test was completed.

All CPET were supervised by a physician and performed using a progressive incremental ramp protocol on a treadmill (Marquette MAX 1 treadmill, Marquette Electronics Inc., Milwaukee, WI, USA) integrated with a metabolic system (CPX Express, Medgraphics, Cardiorespiratory Diagnostic Systems, Medical Graphics Corporation, St. Paul, MN, USA) until patients complained of physical exhaustion or maximal capacity. During the procedure and recovery phase, there was continuous monitoring of the patient’s heart rhythm, peripheral oxygen saturation, blood pressure, and oxygen consumption ($V_{O2}$). CPET was terminated in case of sudden arrhythmias, hypotension (or fall of systolic blood pressure >10 mmHg), repolarization abnormalities, or clinical symptoms suggestive of an underlying myocardial ischemia [16]. We did not exclude patients with a respiratory exchange ratio (RER) <1.05. As a measure of the aerobic capacity, we assessed predicted peak oxygen consumption (p$V_{O2}$) and the anaerobic threshold (AT). To evaluate for ventilation/perfusion abnormalities, we also recorded the ventilatory equivalent of carbon dioxide (VE/VC$O2$) and partial pressure of end-tidal carbon dioxide (PET$CO2$) at AT.

2.7. Statistical Analysis

Categorical variables are reported as absolute values and percentages. Continuous variables are expressed as median (interquartile range (IQR)) or mean ± standard deviation.
(SD). The normality of continuous variables was verified with the Kolmogorov–Smirnov test and Q–Q plot. Categorical variables were compared with the chi-square test and the Fisher exact test when necessary. We compared continuous variables with the Student t-test or Mann–Whitney U test. A Spearman test was performed to analyze the correlation between CPET with the 6-MWT and lung function test. Scale scores of KCMQ were transformed to a 0–100 range by subtracting the lowest possible scale score, dividing by the range of the scale, and multiplying by 100. We performed the statistical analyses with the use of R software, version 3.6.1 (R Project for Statistical Computing) and IBM SPSS Statistics, Version 26.0. Armonk, NY: IBM Corp. Differences were statistically significant when the p-value was <0.05.

3. Results

In the study period, a total of 522 patients were admitted due to moderate–severe COVID-19 and 25% died [17]. A total of 53 patients met the inclusion criteria. In addition, 17 ambulatory patients were also included, leading to a final study population of 70 patients (see Supplementary Figure S1).

3.1. Main Baseline Characteristics and Predictors of Persistent Dyspnea

The main findings are listed in Table 1. The mean follow-up time of the second visit was 181 ± 42 days. Patients were subdivided into those with persistent dyspnea (n = 41, 58.6%) vs. asymptomatic (n = 29, 41.4%), with a greater rate of females (73.2 vs. 51.7%; p = 0.065) among those who complained of dyspnea. We did not observe any difference according to demographic variables and main comorbidities. Inpatients had a similar length of hospital stay and/or previous specific COVID-19 therapies. The need for hospital admission was not related to a greater rate of persistent dyspnea in the follow-up after multivariate adjustment analysis (data not shown).

Table 1. Baseline characteristics and main features during mid-term follow-up in recovered COVID-19 patients according to the presence of persistent dyspnea.

| Variable                  | All Population  n = 70 | Persistent Dyspnea * n = 41 (58.6) | No Residual Dyspnea n = 29 (41.4) | p-Value |
|---------------------------|------------------------|-----------------------------------|-----------------------------------|---------|
| **Demographics, anthropometric data, and comorbidities** |                         |                                    |                                   |         |
| Female sex                | 45 (64.3)              | 30 (73.2)                         | 15 (51.7)                         | 0.065   |
| Age (years)               | 54.8 ± 11.9            | 54.9 ± 10.5                       | 54.6 ± 13.9                       | 0.914   |
| BMI (kg/m²)               | 27.2 ± 4.6             | 28 ± 4.9                          | 26 ± 3.9                          | 0.067   |
| BSA (m²)                  | 1.82 ± 0.18            | 1.81 ± 0.18                       | 1.84 ± 0.18                       | 0.423   |
| CKD **                    | 3 (4.4)                | 3 (7.3)                           | 0                                 | 0.271   |
| Diabetes                  | 3 (5.9)                | 3 (10.3)                          | 0                                 | 0.249   |
| Dyslipidemia              | 13 (19.1)              | 7 (17.1)                          | 6 (22.2)                          | 0.597   |
| Hypertension              | 18 (26.5)              | 12 (29.3)                         | 6 (22.2)                          | 0.519   |
| Hypothyroidism            | 11 (16.2)              | 7 (17.1)                          | 4 (14.8)                          | 0.999   |
| IHD                       | 1 (1.5)                | 0                                 | 1 (3.7)                           | 0.397   |
| Prior pulmonary disease   | 5 (7.4)                | 3 (7.3)                           | 2 (7.4)                           | 0.999   |
| Prior rheumatic disease   | 4 (7.5)                | 4 (9.8)                           | 0                                 | 0.146   |
| Prior stroke/TIA          | 1 (1.5)                | 1 (2.4)                           | 0                                 | 0.999   |
| **Treatment during hospitalization †** |                         |                                    |                                   |         |
| LOS (days)                | 8 (6–11.5)             | 8 (6–11)                          | 8 (6–13)                          | 0.954   |
| Anticoagulation           | 7 (13.2)               | 3 (9.7)                           | 4 (18.2)                          | 0.703   |
| Azithromycin              | 49 (92.5)              | 29 (93.5)                         | 20 (90.9)                         | 0.999   |
| Hydroxychloroquine        | 50 (94.3)              | 28 (90.3)                         | 22 (100)                          | 0.258   |
| Glucocorticoids           | 29 (54.7)              | 15 (48.4)                         | 14 (63.6)                         | 0.272   |
| Lopinavir/Ritonavir       | 51 (96.2)              | 29 (93.5)                         | 22 (100)                          | 0.505   |
| Statins                   | 4 (7.8)                | 2 (6.9)                           | 2 (9.1)                           | 0.999   |
| Variable                        | All Population n = 70 | Persistent Dyspnea * n = 41 (58.6) | No Residual Dyspnea n = 29 (41.4) | p-Value |
|--------------------------------|-----------------------|-------------------------------------|-----------------------------------|---------|
| **Symptoms during follow-up**  |                       |                                     |                                   |         |
| KCCQ summary score             | 70.0 ± 19.4           | 60.1 ± 18.6                         | 82.8 ± 11.3                       | <0.001  |
| Chest pain                     | 8 (11.4)              | 7 (17.1)                            | 1 (3.4)                           | 0.128   |
| Fatigue                        | 20 (28.6)             | 17 (41.5)                           | 3 (10.3)                          | 0.005   |
| Headache                       | 10 (14.3)             | 6 (14.6)                            | 4 (13.8)                          | 0.999   |
| Myalgia                        | 6 (9.8)               | 4 (0.8)                             | 2 (6.9)                           | 0.999   |
| Neurological symptoms ‡        | 14 (20)               | 5 (12.2)                            | 9 (31)                            | 0.052   |
| Palpitations                   | 10 (14.3)             | 6 (14.6)                            | 4 (13.8)                          | 0.999   |

Abbreviations: CKD: chronic kidney disease; IHD: ischemic heart disease; KCCQ: Kansas City Cardiomyopathy Questionnaire; TIA: transient ischemic attack; LOS: length of stay. * Persistent dyspnea was defined as NYHA ≥ II. ** Chronic kidney disease was defined as a glomerular filtration rate of <60 mL/min or need for dialysis. † Only applies to those with prior hospitalization. ‡ Includes paresthesia, olfactory, and taste abnormalities. Values are median (IQR), mean ± SD, or n (%). Bold indicates significative differences (p < 0.05).

3.2. Main Differences in KCCQ Score, Laboratory Parameters, and Echocardiographic Findings According to the Presence of Persistent Dyspnea

Patients with persistent dyspnea presented lower global KCCQ scores, both in the physical and emotional domains (p < 0.001) (see Figure 1). There were no significant differences (p > 0.05) in hemoglobin (14 (13.1–15.2) vs. 14.2 (13.7–16) g/dL), hs-CRP (1.75 (1–4.25) vs. 1.2 (1–2.15) mg/L), IL-6 (3.6 (2.6–4.7) vs. 3.2 (2.5–3.7) pg/mL), ferritin (94.3 (46.1–142.1) vs. 145.3 (51.6–181.2) ng/mL), D-dimer (268 (221–352) vs. 246 (180–384) ng/mL), and NT-ProBNP (37 (19.5–55.4) vs. 65 (29–127) pg/mL) in either group, with the exception of the neutrophil-to-lymphocyte ratio (1.8 (1.17–2.12) vs. 1.32 (0.98–1.76); p = 0.022). A detailed summary of all parameters and some additional parameters are summarized in Table 2. Notably, inpatients showed a trend towards normalization (from hospital admission to follow-up) of all the inflammatory indices (hs-CRP, IL-6, ferritin, and D-dimer) and lymphocyte count (see Figure 2), irrespective of the persistence of symptoms.

Figure 1. Quality of life assessment with Kansas City Cardiomyopathy Questionnaire (KCMQ). * (p < 0.01) and ** (p < 0.001) indicate significant differences.
Figure 2. Temporal dynamic changes of inflammatory markers and lymphocytes from hospital admission to follow-up in the hospitalized cohort. * Excludes outside values; ¥ ($p < 0.05$); † ($p < 0.01$); ‡ ($p < 0.001$).

Table 2. Echocardiography, cardiopulmonary exercise test during, pulmonary function test during mid-term follow-up in recovered COVID-19 patients.

| Laboratory markers                  | All Population n = 70 | Persistent Dyspnea * n = 41 (60) | No residual Dyspnea n = 29 (40) | $p$-Value |
|-------------------------------------|-----------------------|-----------------------------------|----------------------------------|-----------|
| **Albumin (g/L)**                   | 4.5 (4.4–4.7)         | 4.5 (4.4–4.7)                     | 4.5 (4.4–4.6)                    | 0.177     |
| **AST (UI/L)**                      | 19 (16–25)            | 21 (17–25)                        | 17 (13–22)                       | 0.054     |
| **C-reactive protein (mg/L)**       | 1.3 (1–2.8)           | 1.75 (1–4.25)                     | 1.2 (1–2.15)                     | 0.173     |
| **Creatinine (mg/dL)**              | 0.84 (0.75–0.98)      | 0.82 (0.76–0.98)                  | 0.85 (0.75–0.97)                 | 0.995     |
| **D-dimer (ng/mL)**                 | 265 (188–377)         | 268 (221–352)                     | 246 (180–384)                    | 0.581     |
| **Ferritin (ng/mL)**                | 113.1 (50.1–159.1)    | 94.3 (46.1–142.1)                 | 145.3 (51.6–181.2)               | 0.063     |
| **Interleukin-6 (pg/mL)**           | 3.42 (2.6–4.4)        | 3.6 (2.6–4.7)                     | 3.2 (2.5–3.7)                    | 0.174     |
| **Hemoglobin (g/dL)**               | 14 (13.5–15.3)        | 14 (13.1–15.2)                    | 14.2 (13.7–16)                   | 0.107     |
| **Lymphocytes (cells/mm$^3$)**      | 2,185 (1800–2790)     | 2200 (1660–2790)                  | 2170 (1850–2510)                 | 0.638     |
| **Neutrophil/Lymphocyte**           | 1.54 (1.08–2.04)      | 1.8 (1.17–2.12)                   | 1.32 (0.98–1.76)                 | 0.022     |
| **NT-ProBNP (pg/mL)**               | 41 (23–68)            | 37 (19.5–55.4)                    | 65 (29–127)                      | 0.051     |
| **Hs TnT (pg/mL)**                  | 5.4 (3.1–7.54)        | 5.5 (3.2–7)                       | 5.3 (3.2–9.6)                    | 0.504     |
| **TSH (mU/L)**                      | 2.05 (1.68–3.24)      | 2.11 (1.66–3.4)                   | 1.97 (1.7–2.69)                  | 0.722     |

Resting echocardiographic findings

| LAVI (mL/m$^2$)                     | 22.1 (17.7–27.8)      | 21.2 (18.3–30)                   | 22.5 (17.7–26.1)                 | 0.740     |
| LVEF (%)                            | 64 (59–68)            | 65 (59–68)                       | 63 (60–69)                       | 0.962     |
| LVEDVi (mL/m$^2$)                    | 75 (66–100)           | 41.2 (36.2–50.6)                 | 45.3 (40.5–54.2)                 | 0.123     |
| LVESVi (mL/m$^2$)                    | 16.2 (12.3–20.1)      | 14.1 (12.4–21)                   | 16.7 (14–21)                     | 0.194     |
| Mitral E/A ratio                    | 0.9 (0.76–1.22)       | 0.89 (0.79–1.19)                 | 0.93 (0.75–1.27)                 | 0.697     |
| Mitral e’ lateral                   | 0.11 (0.09–0.14)      | 0.8 (0.09–0.13)                  | 0.11 (0.09–0.11)                 | 0.822     |
Table 2. Cont.

| All Population n = 70 | Persistent Dyspnea * n = 41 (60) | No residual Dyspnea n = 29 (40) | p-Value |
|-----------------------|-----------------------------------|---------------------------------|---------|
| Average E/e´ ratio    | 6.5 (4.9–7.9)                    | 6.6 (4.9–8.9)                   | 6.2 (5–7.3) | 0.284 |
| TAPSE (mm)            | 23 (20–26)                       | 23 (20–27)                      | 23 (22–25) | 0.472 |
| S´ (cm/sec)           | 13 (12–15)                       | 13 (12–14.5)                    | 13 (12–15) | 0.392 |
| RVSP (mmHg)           | 19 (15–24)                       | 22 (18–26)                      | 18 (12–19) | 0.020 |
| Global longitudinal strain (%) | 20 (22–19) | 20 (22–19) | 20 (22–19) | 0.806 |

Cardiopulmonary exercise test

|                                | All Population n = 70 | Persistent Dyspnea * n = 41 (60) | No residual Dyspnea n = 29 (40) | p-Value |
|--------------------------------|-----------------------|-----------------------------------|---------------------------------|---------|
| Breathing reserve (%)          | 41 (32–51)            | 46 (30–54)                        | 40 (36–46)                      | 0.319   |
| RER                            | 1.11 (1.05–1.21)      | 1.08 (1.05–1.16)                  | 1.13 (1.05–1.28)                | 0.172   |
| Peak Vo2 (ml/min/kg)           | 19.4 (17.2–24.8)      | 17.8 (15.8–21.2)                  | 22.8 (18.8–27.7)                | <0.001  |
| % of predicted pVo2            | 88 (76–100)           | 77.8 (64–92.5)                    | 99 (88–105)                     | <0.001  |
| Vo2 at AT1 (ml/min/kg)         | 15.4 (12–19.2)        | 13.6 (9.2–17)                     | 18.3 (15.2–19.5)                | 0.003   |
| % of predicted Vo2 / HR        | 101 (83–110)          | 98 (73–110)                       | 106 (96–110)                    | 0.054   |
| VE/Vco2 slope                  | 30.3 (27.5–34.9)      | 32 (28.1–37.4)                    | 29.4 (26.9–31.4)                | 0.022   |
| VE/Vco2 at AT1                 | 34.7 (32.3–39.5)      | 37.2 (31.5–42.3)                  | 33.7 (32.5–36.4)                | 0.194   |
| PETCO2 (mmHg) at AT1           | 38 (33.5–39.5)        | 34.5 (32–39)                      | 38 (36–40)                      | 0.025   |
| Resting HR (beats/min)         | 79 (71–85)            | 78 (70–80)                        | 80 (74–86)                      | 0.357   |
| Peak HR (beats/min)            | 155 (140–163)         | 148 (140–159)                     | 161 (147–169)                   | 0.018   |
| % of predicted HR              | 90.3 (83.9–97.4)      | 87 (79.3–94.5)                    | 95 (88–100)                     | 0.003   |
| Resting O2 saturation (%)      | 97 (96–98)            | 97 (96–98)                        | 97 (96–98)                      | 0.620   |
| Peak O2 saturation (%)         | 97 (96–98)            | 97 (96–98)                        | 97 (96–98)                      | 0.388   |
| Resting systolic BP (mmHg)     | 139 (124–146)         | 140 (125–150)                     | 123 (134–142)                   | 0.205   |
| Peak systolic BP (mmHg)        | 143 (160–177)         | 155 (139–175)                     | 160 (151–177)                   | 0.319   |
| Resting diastolic BP (mmHg)    | 86 (77–95)            | 90 (80–97)                        | 82 (75–89)                      | 0.034   |
| Peak diastolic BP (mmHg)       | 90 (81–100)           | 90 (82–106)                       | 91 (80–95)                      | 0.443   |

Pulmonary lung function

|                                | All Population n = 70 | Persistent Dyspnea * n = 41 (60) | No residual Dyspnea n = 29 (40) | p-Value |
|--------------------------------|-----------------------|-----------------------------------|---------------------------------|---------|
| DLco % of predicted            | 88.8 (80–97)          | 86 (74.5–95.3)                    | 90 (83.5–100)                   | 0.098   |
| Kco % of predicted             | 95.3 (88.7–109)       | 94.6 (86.5–107)                   | 96 (89.5–105)                   | 0.493   |
| FEV1 % of predicted            | 112 (103.5–121.5)     | 113 (102–122)                     | 115 (105–124)                   | 0.690   |
| FVC % of predicted             | 116 (105–131)         | 115 (104–132.5)                   | 116 (108.5–120)                 | 0.989   |
| FEV1/FVC (%)                   | 100 (91.6–105)        | 98.5 (86.5–106)                   | 102 (97–104)                    | 0.466   |
| RV % of predicted              | 101 (89.8–118.5)      | 106.5 (94.3–119)                  | 95 (85–109)                     | 0.138   |
| TLC % of predicted             | 100 (96.5–111)        | 100 (96–112.7)                    | 101 (97–109)                    | 0.801   |
| 6-MWT distance (meters)        | 558 (500–615)         | 535 (467–600)                     | 611 (550–650)                   | 0.001   |

Abbreviations: 6-MWT: six-minute walking test; AT: anaerobic threshold; DLco: carbon monoxide diffusion capacity; E/e´: ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity; FEV1: forced expiratory volume in 1 min; FVC: forced vital capacity; HR: heart rate; LAVI: left atrial volume indexed; LVEF: left ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume indexed; LVEF: left ventricular end-diastolic volume; METs: metabolic equivalents; RV: residual volume; TLC: total lung capacity. * Persistent dyspnea was defined as NYHA ≥ II. Values are median (IQR). Bold indicates significative differences (p < 0.05).

Resting echocardiography findings among COVID-19 survivors are summarized in Table 2. The left ventricular systolic and diastolic functions were comparable between the study groups. No severe valvular heart disease was observed, only mild mitral regurgitation was presented in 11 patients (19.5 vs. 10.3%; p = 0.342) and mild aortic regurgitation in 6 patients (12.2 vs. 3.4%; p = 0.389). In addition, all patients had a normal right ventricular function and no indirect signs of pulmonary hypertension, though symptomatic patients had a greater estimated right ventricular pressure (22 (18–26) vs. 18 (12–19) mmHg; p = 0.020).

3.3. Cardiac and Pulmonary Function Test

A summary of the results from the cardiopulmonary evaluation is reported in Table 2. Overall, there were no differences in respiratory mechanics at follow-up. Whereas patients with persistent dyspnea showed a trend towards a lower predicted DLco (84 (70–92.1) vs. 91 (85–102); p = 0.098).
During CPET, compared with asymptomatic controls, patients with persistent dyspnea presented lower predicted $pV_{O2}$ (77.8 (64–92.5) vs. 99 (88–105); $p < 0.001$) and $pV_{O2}$ at AT (13.6 (9.2–17) vs. 18.3 (15.2–19.5); $p = 0.003$). Both groups presented similar RER (1.08 (1.05–1.16) vs. 1.13 (1.05–1.28); $p = 0.172$) and % of predicted $O_2$ pulse (98 (73–110) vs. 106 (96–110); $p = 0.054$). Regarding the ventilatory efficiency, a higher VE/VCO₂ slope (32 (28–37.4) vs. 29.4 (26.9–31.4); $p = 0.022$) and lower PETCO₂ at AT (34.5 (32–39) vs. 38 (36–40); $p = 0.025$) in patients with persistent dyspnea were detected. Neither desaturation on exercise nor differences in breathing reserve were detected. Blood pressure was comparable at any given moment but peak heart rate (87 (79.3–94.5) vs. 95 (88–100); $p = 0.003$) was lower in symptomatic patients although within normal values.

Moreover, symptomatic patients achieved shorter distances in the 6-MWT (535 (467–600) vs. 611 (550–650) m; $p = 0.001$), presenting a positive correlation with $pV_{O2}$ (R = 0.533; $p < 0.001$) in the global study population. No patient presented oxygen desaturation during the 6-MWT. The main findings are summarized in Table 2.

### 3.4. Hospitalized and Ambulatory Patients

Outpatient clinical and main hospitalized clinical and functional characteristics are shown in Supplementary Tables S1 and S2. We did not observe differences in the main baseline characteristics. On the contrary, irrespective of the previous history of hospitalization, symptomatic patients presented a significantly lower exercise tolerance compared to their homologs in terms of predicted $pV_{O2}$ and total distance in the 6-MWT. We also observed a lower QoL in the KCCQ in both groups. The main features associated with persistent dyspnea, both in ambulatory and hospitalized patients, are presented in Figure 3.

![Figure 3. Predictors of dyspnea among hospitalized and ambulatory patients.](image)

#### 3.5. Summary of Published Evidence

We also summarized all the current data regarding persistent symptoms after acute COVID-19 (see Table 3). According to the available evidence [3–8,18–26], the most frequent symptoms during follow-up are dyspnea and fatigue. Six studies evaluated pulmonary function, detecting a decrease in DLCO with a normal FEV1/FVC in the global post-COVID-19 population at short-term follow-up [5–8,24]. Two studies evaluated the functional status with the 6-MWT [5,21,24], suggesting a decrease in functional capacity. One study reported data about outpatients without prior hospitalization in early convalescence, the most common persisting symptoms were fatigue, dyspnea, and cough [27]; no functional tests were performed in this setting.
Table 3. Summary of the available data of persistent symptoms after acute COVID-19.

| First Author                  | Journal/Year     | Design                  | Number of Patients | Timing of Assessment | Clinical Findings                     | Biomarkers                | Functional Findings                                      | QoL Assessment |
|-------------------------------|------------------|-------------------------|--------------------|----------------------|----------------------------------------|---------------------------|-----------------------------------------------------------|---------------|
| Garrigues et al. [3]          | *J. Infection* /2020 | Single-center Prospective | 120                | >3 months            | Dyspnea 41.7% Fatigue 55%             | Not reported              | Not reported                                              | Yes           |
| Carfi et al. [4]              | *Jama* /2020     | Single-center Prospective | 143                | 2 months             | Dyspnea 43.4% Fatigue 53.1%           | Not reported              | CRP 9.7 ± 13.8 LDH 175.5 ± 43.6 Lymphocytes 1.6 ± 0.5    | Yes           |
| Huang et al. [5]              | *Eur. Respir. J.* /2020 | Single-center Retrospective | 57                 | 1 month              | Dyspnea 7% Cough 10.5%                | Not reported              | 6-MWD 562 ± 45.3 FEV1/FVC 81.2 ± 6.1 DLCO 78.4 ± 3.6    | No            |
| Frija-Masson et al. [6]       | *Eur. Respir. J.* /2020 | Single-center Retrospective | 50                 | 1 month              | (Only assessed asymptomatic)          | Not reported              | FEV1/FVC 81 (75–87) DLCO 80 (70–92) KCO 94 (78–108)    | No            |
| Mo et al. [7]                 | *Eur. Respir. J.* /2020 | Single-center Retrospective | 110                | Hospital discharge   | (Evaluated on the day or day after discharge) | Not reported              | DLCO 78.2 ± 14.3 KCO 92.1 ± 16.7                         | No            |
| Zhao et al. [8]               | *Eclinicalmedicine* /2020 | Multi-center Retrospective | 55                 | >3 months            | Dyspnea 14.5% Fatigue 16.4%           | D-dimer 230 vs. 420 Lymphocyte 1.42 vs. 1.22 | Abnormal pulmonary function 14 patients | No            |
| Carvalho-Schneider et al. [18]| *Clin. Microbiol. Infect.* /2020 | Single-center Prospective | 150                | 1 and 2 months       | Dyspnea 10.7% and 7.7% Chest pain 18% and 13% Flu-like 36% and 21% | Not reported              | D-dimer 230 vs. 420 Lymphocyte 1.42 vs. 1.22 | No            |
| Rosales-Castillo et al. [19]  | *Med. Clin. (Barc.)* /2020 | Single-center Retrospective | 118                | >1 month             | Dyspnea 31.4% Fatigue 30.5%            | Not reported              | CRP 1 (1–4) D-dimer 384 (242–665) Lymphocytes 1.94 (1.44–2.52) | No            |
| Mandal et al. [20]            | *Thorax* /2020    | Single-center Prospective | 384                | >1 month             | Dyspnea 53% Fatigue 69% Cough 34%      | Not reported              | Not reported                                             | No            |
| First Author | Journal/Year | Design | Number of Patients | Timing of Assessment | Clinical Findings | Biomarkers | Functional Findings | QoL Assessment |
|--------------|--------------|--------|-------------------|---------------------|-------------------|------------|---------------------|---------------|
| Daher et al. [21] | Respir. Med./2020 | Single-center Prospective | 33 | 6 weeks | Dyspnea 33%  
Fatigue 45%  
Cough 33% | CRP 2 (1.1–7.9)  
LDH 213 (196–227)  
Ferritin 154.6 (82–364)  
NT-ProBNP 183 (43–474)  
Hs Troponin-T 8 (4–21) | 6-MWD 380 (180–470)  
FEV1/FVC 79 (76–85)  
DLCO 65 (53–73)  
KCO 77 (69–95)  
LVEF 52 (50–52) | Yes |
| Göertz et al. [22] | ERJ Open Res./2020 | Multi-center Prospective | 2113 | 3 months | Dyspnea 71%  
Fatigue 87%  
Cough 38% | Not reported | Not reported | No |
| Xiong et al. [23] | Clin. Microbil. Infect./2020 | Longitudinal study | 538 | 3 months | Dyspnea 21%  
Fatigue 28.3% | Not reported | Not reported | No |
| Jelle et al. [24] | Respir. Med./2020 | Cross-sectional | 220 | 10 weeks | Dyspnea 47%  
Fatigue 66% | Not reported | Not reported | No |
| Tabada et al. [25] | J. Infection/2020 | Cross-sectional | 183 | 6 months | Dyspnea 10.9% | Not reported | Not reported | Yes |
| McCue et al. [26] | Intensive Care Med./2020 | Not reported | 30 | 12–16 weeks | Pain 67% | Not reported | Not reported | Yes |
| Tenforde et al. [27] | Mortal. Wkly. Rep./2020 | Not reported | 175 | 2–3 weeks | Dyspnea 26%  
Fatigue 35%  
Cough 43% | Not reported | Not reported | No |

Abbreviations: 6-MWT: six-minute walking test; CRP: C-reactive protein; DLCO: carbon monoxide diffusion capacity; FEV1/FVC: forced expiratory volume in 1 min/forced vital capacity ratio; LDH: lactate dehydrogenase; LVEF: left ventricular ejection fraction.
4. Discussion

This single-center prospective study evaluated persistent dyspnea throughout analyses of patients with prior history of SARS-CoV-2 infection. The main findings are as follows: (1) more than half of the patients complained of persistent dyspnea in the midterm follow-up irrespective of the need for hospital admission and despite healed infection and normalization of inflammatory markers; (2) these subjective symptoms presented objective translation as reduced QoL (KCCQ) and exercise performance (6-MWT and CPET); and (3) conversely, the indices of cardiac and ventilatory inefficiency measured during CPET suggested a potential ventilation/perfusion mismatch.

4.1. Rationale for Post-COVID-19 Symptom Persistence

Persistent symptoms were more common in women but not in elderly patients. Although in our study 7% of the patients required ICU admission, the persistence of symptoms was related neither to ICU nor to hospital admission. The high rate of post-COVID-19 symptomatic patients is in agreement with alternative coronavirus outbreaks. Although several studies have explored the symptom burden [3–8,18–26], similarly reporting a substantial proportion of patients with persistent dyspnea and fatigue, limited information exists regarding exercise capacity [5–8,24]. Two prior studies have reported a decreased 6-MWT distance among survivors [5,21,24]. Such findings, as well as the lower scores on the QoL questionnaire detected in our research, can vary depending on several conditions [11] and therefore have a limited prognostic value in this context. The significantly lower exercise capacity (measured as predicted pV\textsubscript{O}2) in the CPET has been previously related to increased mortality in alternative contexts [16,28].

The CPET data in symptomatic patients are compatible with ventilatory inefficiency (high VE/V\textsubscript{CO}2 with a lower PET\textsubscript{CO}2) strongly suggestive of a ventilation/perfusion mismatch due to pulmonary vasculopathy [29] and also supported by a mild reduction of DL\textsubscript{CO} already described by other authors [5–8,24]. This pulmonary vascular disease, according to our findings, does not seem to have a component of cardiac contribution, persistent inflammation, iron deficiency, or air-flow limitation. Despite the very limited shreds of evidence from autopsy reports, several factors are supporting this vascular mechanism. First, endothelial injury has been widely described in SARS-CoV-2 infected patients, explaining multiorgan affection [30]. Second, postmortem analyses have reported diffuse alveolar damage and small microthrombi in pulmonary capillaries as the most characteristic findings [31,32]. Third, intravascular fibrin aggregates in pulmonary vessels were the most common finding regardless of the type of pulmonary injury [33]. Fourth, endothelial dysfunction has been linked before to activation of the coagulation cascade in COVID-19 patients [30]. Fifth, intussusceptive angiogenesis was also observed in lungs from COVID-19 patients [32], which may, in theory, disrupt the structure of the microcirculation and has been previously described in chronic thromboembolic pulmonary hypertension [34].

Could the persistence of microvascular thrombus be the hallmark of post-COVID-19 dyspnea? This hypothesis could be supported by the fact that 42.5% of our study population underwent computed tomography and 41% compression venous ultrasonography during follow-up without any evidence of thrombi in the pulmonary or femoral vessels. Besides, Ong et al. reported a decreased exercise capacity amongst SARS-CoV survivors that was not explained by pulmonary or ventilatory function [35]. Similarly, Jelle et al. proposed that restriction among COVID-19 survivors did not explain the residual symptoms, and low DL\textsubscript{CO} was not explained either by anemia [24]. It thus appears that circulatory impairment might be the missing link that could explain some of the residual symptoms in post-COVID-19 syndrome, but we should keep in mind that the mechanism remains obscure. The ventilatory inefficiency observed in our symptomatic cohort is also observed in the hyperventilation syndrome [36], which has been recently suggested as a potential mechanism of the post-COVID-19 syndrome [37]. In fact, this syndrome has
been described in broad lung conditions, such as acute pulmonary embolism, pneumonia, chronic interstitial lung diseases, and after viral infections [36].

Motiejunaite et al. reviewed eight patients with residual symptoms after COVID-19 infection and reported similar findings to us. All of them showed a decreased exercise capacity, and five patients showed an elevated VE/V\textsubscript{CO2} ratio suggestive of hyperventilation syndrome [37]. In this respect, hyperventilation may induce hypocapnia and it is believed to be caused by an abnormal ventilatory control by either stimulation of activator systems or suppression of inhibitory systems. This hyperventilation-induced hypocapnia could explain the persisting exercise intolerance and CPET pattern observed in these patients. However, Crisafulli et al. evaluated patients with persistent hypocapnia and did not observe an increased rate of persistent dyspnea or fatigue, but it was associated with impaired diffusion [38]. Because both can present with a similar pattern in CPET [36], future studies with ventilation/perfusion scanning are warranted.

Finally, another potential mechanism could be the autonomic dysfunction. Maladaptive function of the autonomic nervous system in COVID-19 survivors may contribute to the persistence of fatigue, shortness of breath, and palpitations [37]. Consistent with this hypothesis, Dorelli et al. observed a slower heart rate recovery suggestive of dysautonomia among post-COVID-19 patients with ventilatory inefficiency [39]. The cause of this autonomic dysfunction is not clear but probably involves infection-mediated endothelial injury that causes an abnormal activation of the parasympathetic nervous system.

4.2. Prognostic Implications

The aforementioned impaired functional parameters suggest that post-COVID-19 patients with persistent symptoms should undergo dedicated follow-up programs. Not surprisingly, these findings are also similar to those reported in the previous coronaviruses during early convalescence and long-term follow-up [9,10,35]. Persistent symptoms amongst outpatients are not rare [22,27]. According to our findings, a low aerobic capacity and QoL could be a constant among patients developing this kind of sequelae, irrespective of the clinical course during the infection. Nonetheless, the mechanism and the prognostic relevance of these findings remain unclear. Whether life expectancy might be modified due to post-COVID-19 syndrome is a question yet to be answered, as similar findings in other cardiac or respiratory conditions are considered predictors of mortality [16,28,39].

4.3. Limitations

Despite the prospective nature of the present study, the main limitation is the relatively modest sample size from a single-center and the lack of pre-COVID-19 cardiopulmonary functional tests; thereby, we cannot rule out that previous non-diagnosed chronic conditions may interfere despite the strict inclusion criteria. Second, patients did not undergo CPET with invasive hemodynamic monitoring, arterial blood gas analysis, or exertional echocardiography, even though it might have been more accurate to evaluate exercise-induced dyspnea. Third, we chose a heterogeneous sample to mimic a more real-world clinical scenario, however, it is also a potential limitation that limits its generalizability. Fourth, a potential selection bias cannot be ruled out, as symptomatic patients may be more predisposed to collaborate or seek early medical attention. Finally, we cannot draw causal inferences based on our study results, which should be considered hypothesis-generating. Future prospective studies should be encouraged to validate and properly understand if the reported data are the result of COVID-19.

5. Conclusions

In this study, >50% of COVID-19 survivors present a symptomatic functional impairment irrespective of age or prior hospitalization. Our findings are consistent with a perfusion/ventilation mismatch that likely reflects gas exchange inefficiency or hyperventilation syndrome. On this basis, systematic follow-up of patients with persistent symptoms
following SARS-CoV-2 infection, including cardiopulmonary functional tests, should be encouraged at longer term follow-up.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/jcm10122591/s1, Table S1: Baseline characteristics and main features during mid-term follow-up in recovered COVID-19 patients according to the presence of persistent dyspnea in outpatients, Table S2: Baseline characteristics and main features during mid-term follow-up in recovered COVID-19 patients according to the presence of persistent dyspnea among hospitalized patients, Figure S1: Schematic flowchart of the recovered COVID-19 patients included in the study, showing main findings.

**Author Contributions:** Conceptualization, Á.A. and C.Y.-F.; methodology, Á.A., I.C. and D.A.-O.; software, M.C.-M.; validation, P.C., W.H. and M.M.-M.; formal analysis, M.C.-M.; investigation, Á.A., C.Y.-F., M.G.-G., J.T., S.J.-L., R.L., L.F.-P., R.S.-G., B.d.V.-S., A.R.-P., E.S.-P.; resources, D.C. and C.D.-V.; data curation, P.C., W.H. and M.M.-M.; writing—original draft preparation, Á.A., C.Y.-F.; writing—review and editing, Á.A., C.Y.-F., R.L., A.U. and I.J.A.-S.; visualization, Á.A. and M.C.-M.; supervision, J.A.S.R.; project administration, Á.A. and C.B.; funding acquisition, Á.A. and I.J.A.-S. All authors have read and agreed to the published version of the manuscript.

**Funding:** The present study was partially granted by Gerencia Regional de Salud de Castilla y León under grant number GRS COVID 111/A/20 and a grant from the Spanish Society of Cardiology SEC/FEC-INVCLI 2.

**Institutional Review Board Statement:** The study protocol (CASVE PI-20-1894) was approved by the local ethics committee of “Hospital Clínico Universitario de Valladolid”.

**Informed Consent Statement:** All patients provided written informed consent before inclusion.

**Data Availability Statement:** The data presented in this study are available upon reasonable request from the corresponding author. The data are not publicly available due to them containing information that could compromise the privacy of the research participants.

**Acknowledgments:** This paper and the research behind it would not have been possible without the exceptional support of all the co-workers from the multi-disciplinary COVID-19 team.

**Conflicts of Interest:** The authors declare that they have no conflict of interest.

**Abbreviations**

- 6-MWT: Six-minute walking test
- COVID-19: Coronavirus disease 2019
- CPET: Cardiopulmonary exercise test
- DLCO: Carbon monoxide diffusion capacity
- KCCQ: Kansas City Cardiomyopathy Questionnaire
- PETCO2: Partial pressure of end-tidal carbon dioxide
- QoL: Quality of Life
- SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2
- VE/VCO2: Ventilatory equivalent of carbon dioxide
- VO2: Oxygen consumption

**References**

1. Pinney, S.P.; Giustino, G.; Halperin, J.L.; Mechanick, J.I.; Neibart, E.; Olin, J.W.; Rosenson, R.S.; Fuster, V. Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes. *J. Am. Coll. Cardiol.* 2020, 76, 1999–2010. [CrossRef] [PubMed]

2. World Health Organization (WHO). Coronavirus Disease (COVID-19). Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on 5 August 2020).

3. Garrigues, E.; Janvier, P.; Kherabi, Y.; Le Bot, A.; Hamon, A.; Gouze, H.; Doucet, L.; Berkani, S.; Oliosi, E.; Mallart, E.; et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. *J. Infect.* 2020, 81, e4–e6. [CrossRef] [PubMed]

4. Carfi, A.; Bernabei, R.; Landi, F. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* 2020, 324, 603–605. [CrossRef] [PubMed]
5. Huang, Y.; Tan, C.; Wu, J.; Chen, M.; Wang, Z.; Luo, L.; Zhou, X.; Liu, X.; Huang, X.; Yuan, S.; et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir. Res. 2020, 21, 1–10. [CrossRef] [PubMed]

6. Frija-Masson, J.; Debray, M.-P.; Gilberti, M.; Lescure, F.-X.; Travert, F.; Borie, R.; Khalil, A.; Crestani, B.; D’Ortho, M.-P.; Bancal, C. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur. Respir. J. 2020, 56, 2001754. [CrossRef]

7. Mo, X.; Jian, W.; Su, Z.; Chen, M.; Peng, H.; Peng, P.; Lei, C.; Chen, R.; Zhong, N.; Li, S. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur. Respir. J. 2020, 55, 2001217. [CrossRef]

8. Zhao, Y.-M.; Song, W.-B.; Li, Q.-Q.; Xie, H.; Xu, Q.-F.; Jia, J.-L.; Li, L.-M.; Mao, H.-L.; Zhou, X.-M.; et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. eClinicalMedicine 2020, 25, 100463. [CrossRef]

9. Hui, D.S.; Wong, K.T.; Ko, F.W.S.; Tam, L.S.; Chan, D.P.; Woo, J.; Sung, J.J.Y. The 1-Year Impact of Severe Acute Respiratory Syndrome on Pulmonary Function, Exercise Capacity, and Quality of Life in a Cohort of Survivors. Chest 2005, 128, 2247–2261. [CrossRef]

10. Ahmed, H.; Patel, K.; Greenwood, D.; Halpin, S.; Lewthwaite, P.; Salawu, A.; Breen, A.; O’Connor, R.; Jones, A.; et al. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after ICU admission: A systematic review and meta-analysis. J. Rehabil. Med. 2020. [CrossRef]

11. Spertus, J.A.; Jones, P.G.; Sandhu, A.T.; Arnold, S.V. Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care. J. Am. Coll. Cardiol. 2020, 76, 2379–2390. [CrossRef]

12. Lang, R.M.; Badano, L.P.; Mor-Avi, V.; Afilalo, J.; Armstrong, A.; Ernande, L.; Flachskampf, F.A.; Foster, E.; Goldstein, S.A.; Kuznetsova, T.; et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American society of echocardiography and the European association of cardiovascular imaging. Eur. Heart J. Cardiovasc. Imaging 2015, 16, 233–271. [CrossRef]

13. Graham, B.L.; Steenbruggen, I.; Miller, M.R.; Barjaktarevic, I.Z.; Cooper, B.G.; Hall, G.L.; Hallstrand, T.S.; Kaminsky, D.A.; McCarthy, K.; McCormack, M.C.; et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am. J. Respir. Crit. Care Med. 2019, 200, e70–e88. [CrossRef]

14. Graham, B.L.; Brusasco, V.; Burgos, F.; Cooper, B.G.; Jensen, R.; Kendrick, A.; MaIntyre, N.R.; Thompson, B.R.; Wanger, J. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017, 49, 1600016. [CrossRef]

15. Holland, A.E.; Spruit, M.A.; Troosters, T.; Puhan, M.A.; Pepin, V.; Saey, D.; McCormack, M.C.; Carlin, B.W.; Sciurba, F.; Pitta, F.; et al. An official European Respiratory Society/American Thoracic Society technical standard: Field walking tests in chronic respiratory disease. Eur. Respir. J. 2014, 44, 1428–1446. [CrossRef]

16. Balady, G.J.; Arena, R.; Sietsema, K.; Myers, J.; Coke, L.; Fletcher, G.F.; Forman, D.; Franklin, B.; Guazzi, M.; Gulati, T.; et al. Clinician’s Guide to Cardiopulmonary Exercise Testing in Adults. Circulation 2010, 122, 191–225. [CrossRef]

17. Román, J.A.S.; Uribarri, A.; Amat-Santos, I.J.; Aparisi, Á.; Catalá, P.; González-Juanatey, J.R. The presence of heart disease worsens prognosis in patients with COVID-19. Rev. Española Cardiol. 2020, 73, 773–775. [CrossRef]

18. Carvalho-Schneider, C.; Laurent, E.; Lemaignen, A.; Beaufils, E.; Bourbou-Tournois, C.; Laribi, S.; Flament, T.; Ferreira-Maldent, N.; Bruyère, F.; Stefic, K.; et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021, 27, 258–263. [CrossRef]

19. Rosales-Castillo, A.; Ríos, C.G.D.L.; García, J.D.M. Persistencia de manifestaciones clínicas tras la infección COVID-19: Importancia del seguimiento. Med. Clin. 2020, 156, 35–36. [CrossRef]

20. Mandal, S.; Barnett, J.; Brill, S.E.; Brown, J.S.; Denny, E.K.; Hare, S.S.; Heightman, M.; Hillman, T.E.; Jacob, J.; Jarvis, H.C.; et al. ‘Long-COVID’: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 2021, 76, 396–398. [CrossRef]

21. Daher, A.; Balfanz, P.; Cornelissen, C.; Müller, A.; Bergs, I.; Marx, N.; Müller-Wieland, D.; Hartmann, B.; Dreher, M.; Müller, T. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir. Med. 2020, 174, 106197. [CrossRef]

22. Goertz, Y.M.; Van Herck, M.; Delbressine, J.M.; Vaes, A.W.; Meys, R.; Machado, F.V.; Houben-Wilke, S.; Burtin, C.; Posthumus, R.; Franssen, F.M.; et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? EUR Open Res. 2020, 6, 0542–02020. [CrossRef]

23. Xiong, Q.; Xu, M.; Li, J.; Liu, Y.; Zhang, J.; Xu, Y.; Dong, W. Clinical sequelae of COVID-19 survivors in Wuhan, China: A single-centre longitudinal study. Clin. Microbiol. Infect. 2021, 27, 89–95. [CrossRef]

24. Smet, J.; Stylemans, D.; Hanon, S.; Ilsen, B.; Verbanck, S.; Vanderhelst, E. Clinical status and lung function 10 weeks after severe SARS-CoV-2 infection. Respir. Med. 2021, 176, 106276. [CrossRef]

25. Taboada, M.; Cariñena, A.; Moreno, E.; Rodríguez, N.; Domínguez, M.J.; Casal, A.; Riveiro, V.; Díaz-Vieito, M.; Valdés, L.; Álvarez, J.; et al. Post-COVID-19 functional status six-months after hospitalization. J. Infect. 2020, 82, e31–e33. [CrossRef]

26. McCue, C.; Cowan, R.; Quasim, T.; Puxty, K.; McPeake, J. Long term outcomes of critically ill COVID-19 pneumonia patients: Early learning. Intensiv. Care Med. 2021, 47, 240–241. [CrossRef]
27. Tenforde, M.W.; Kim, S.S.; Lindsell, C.J.; Rose, E.B.; Shapiro, N.I.; Files, D.C.; Gibbs, K.W.; Erickson, H.L.; Steingrub, J.S.; Smithline, H.A.; et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network—United States, March–June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 993–998. [CrossRef]

28. Nayor, M.; Houstis, N.E.; Namavivayam, M.; Rouvina, J.; Hardin, C.; Shah, R.V.; Ho, J.E.; Malhotra, R.; Lewis, G.D. Impaired Exercise Tolerance in Heart Failure with Preserved Ejection Fraction. JACC Heart Fail. 2020, 8, 605–617. [CrossRef] [PubMed]

29. Weatherald, J.; Farina, S.; Bruno, N.; Laveneziana, P. Cardiopulmonary Exercise Testing in Pulmonary Hypertension. Ann. Am. Thorac. Soc. 2017, 14, 584–592. [CrossRef] [PubMed]

30. Jin, Y.; Ji, W.; Yang, H.; Chen, S.; Zhang, W.; Duan, G. Endothelial activation and dysfunction in COVID-19: From basic mechanisms to potential therapeutic approaches. Signal Transduct. Target. Ther. 2020, 5, 1–13. [CrossRef] [PubMed]

31. Maiese, A.; Manetti, A.C.; La Russa, R.; Di Paolo, M.; Turillazzi, E.; Frati, P.; Fineschi, V. Autopsy findings in COVID-19-related deaths: A literature review. Forensic Sci. Med. Pathol. 2021, 17, 279–296. [CrossRef] [PubMed]

32. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Stark, H.; Tzankov, A.; et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 2020, 383, 120–128. [CrossRef]

33. De Michele, S.; Sun, Y.; Yilmaz, M.M.; Katsyv, I.; Salvatore, M.; Dzierba, A.L.; Marboe, C.C.; Brodie, D.; Patel, N.M.; Garcia, C.K.; et al. Forty Postmortem Examinations in COVID-19 Patients Two Distinct Pathologic Phenotypes and Correlation with Clinical and Radiologic Findings. Am. J. Clin. Pathol. 2020, 154, 156. [CrossRef]

34. Ackermann, M.; Mentzer, S.J.; Kolb, M.; Jonigk, D. Inflammation and intussusceptive angiogenesis in COVID-19: Everything in and out of flow. Eur. Respir. J. 2020, 56, 2003147. [CrossRef]

35. Ong, K.-C.; Ng, A.-K.; Lee, L.-U.; Kaw, G.; Leow, M.-S.; Earnest, A. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur. Respir. J. 2004, 24, 436–442. [CrossRef]

36. Crisafulli, E.; Gabbiani, D.; Magnani, G.; Dorelli, G.; Busti, F.; Sartori, G.; Girelli, D. Residual Lung Function Impairment Is Associated with Hyperventilation in Patients Recovered from Hospitalised COVID-19: A Cross-Sectional Study. J. Clin. Med. 2021, 10, 1036. [CrossRef]

37. Motiejunaite, J.; Balagny, P.; Arnault, F.; Mangin, L.; Bancal, C.; D’Ortho, M.-P.; Frija-Masson, J. Hyperventilation: A Possible Explanation for Long-Lasting Exercise Intolerance in Mild COVID-19 Survivors? Front. Physiol. 2021, 11, 614590. [CrossRef]

38. Brat, K.; Stastna, N.; Merta, Z.; Olson, L.J.; Johnson, B.D.; Cundrie, I. Cardiopulmonary exercise testing for identification of patients with hyperventilation syndrome. PLoS ONE 2019, 14, e0215997. [CrossRef]

39. Dorelli, G.; Braggio, M.; Gabbiani, D.; Busti, F.; Caminati, M.; Senna, G.; Girelli, D.; Laveneziana, P.; Ferrari, M.; Sartori, G.; et al. Importance of Cardiopulmonary Exercise Testing amongst Subjects Recovering from COVID-19. Diagnostics 2021, 11, 507. [CrossRef]